For the first time in more than a decade, U.S. adult obesity rates have shown a slight but notable decline. A new study published in JAMA Health Forum found that obesity prevalence dropped from 46 percent in 2022 to 45.6 percent in 2023. While modest, the shift is significant after years of steady increases. Researchers suggest that the rise of GLP-1 medications—such as Ozempic and Mounjaro—may be contributing to this change, particularly in regions with higher uptake of these treatments.
Slimmer In the South
The study, which analyzed BMI data from more than 16.7 million adults across the U.S., highlighted the South as the area of the country with the biggest declines, alongside decreases among women and adults aged 66–75. This reflects a big nationwide weight-loss trend, as our own NewBeauty State of Aesthetics data shows 31.3 percent of GLP-1 users aimed to lose 20-40 pounds, while another 27.6 percent set goals of 40-60 pounds.
Obesity Still a Major Concern
While the drop is promising, researchers urge caution. Obesity remains a major health issue, with the CDC reporting that over one-third of U.S. adults are still obese. The study also has its limits, like potential gaps in insurance data and biases in medical records.
A Promising Start
Experts say it’s too early to call this a lasting trend. With weight loss drugs becoming more common and public health efforts evolving, more research is needed to see if this decline will stick. For now, it’s a small but meaningful shift in a long upward climb.
